These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12467624)

  • 1. Design and synthesis of pseudo-symmetric HIV protease inhibitors containing a novel hydroxymethylcarbonyl (HMC)-hydrazide isostere.
    Hidaka K; Kimura T; Hayashi Y; McDaniel KF; Dekhtyar T; Colletti L; Kiso Y
    Bioorg Med Chem Lett; 2003 Jan; 13(1):93-6. PubMed ID: 12467624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic.
    Kiso Y; Matsumoto H; Mizumoto S; Kimura T; Fujiwara Y; Akaji K
    Biopolymers; 1999; 51(1):59-68. PubMed ID: 10380353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of substrate-based peptidomimetic human immunodeficiency virus protease inhibitors containing the hydroxymethylcarbonyl isostere.
    Kiso Y
    Biopolymers; 1996; 40(2):235-44. PubMed ID: 8785365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationship of orally potent tripeptide-based HIV protease inhibitors containing hydroxymethylcarbonyl isostere.
    Mimoto T; Hattori N; Takaku H; Kisanuki S; Fukazawa T; Terashima K; Kato R; Nojima S; Misawa S; Ueno T; Imai J; Enomoto H; Tanaka S; Sakikawa H; Shintani M; Hayashi H; Kiso Y
    Chem Pharm Bull (Tokyo); 2000 Sep; 48(9):1310-26. PubMed ID: 10993230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of highly potent HIV protease inhibitors with activity against resistant virus.
    Lu Z; Raghavan S; Bohn J; Charest M; Stahlhut MW; Rutkowski CA; Simcoe AL; Olsen DB; Schleif WA; Carella A; Gabryelski L; Jin L; Lin JH; Emini E; Chapman K; Tata JR
    Bioorg Med Chem Lett; 2003 May; 13(10):1821-4. PubMed ID: 12729673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
    Mimoto T; Kato R; Takaku H; Nojima S; Terashima K; Misawa S; Fukazawa T; Ueno T; Sato H; Shintani M; Kiso Y; Hayashi H
    J Med Chem; 1999 May; 42(10):1789-802. PubMed ID: 10346931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KMI-008, a novel beta-secretase inhibitor containing a hydroxymethylcarbonyl isostere as a transition-state mimic: design and synthesis of substrate-based octapeptides.
    Shuto D; Kasai S; Kimura T; Liu P; Hidaka K; Hamada T; Shibakawa S; Hayashi Y; Hattori C; Szabo B; Ishiura S; Kiso Y
    Bioorg Med Chem Lett; 2003 Dec; 13(24):4273-6. PubMed ID: 14643307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
    Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
    Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of new inhibitors of HIV-1 protease dimerization with conformationally constrained templates.
    Song M; Rajesh S; Hayashi Y; Kiso Y
    Bioorg Med Chem Lett; 2001 Sep; 11(18):2465-8. PubMed ID: 11549448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of HIV protease inhibitors containing allophenylnorstatine as a transition-state mimic.
    Kiso Y
    Adv Exp Med Biol; 1995; 362():413-23. PubMed ID: 8540352
    [No Abstract]   [Full Text] [Related]  

  • 11. Rational design and synthesis of a novel class of active site-targeted HIV protease inhibitors containing a hydroxymethylcarbonyl isostere. Use of phenylnorstatine or allophenylnorstatine as a transition-state mimic.
    Mimoto T; Imai J; Tanaka S; Hattori N; Takahashi O; Kisanuki S; Nagano Y; Shintani M; Hayashi H; Sakikawa H
    Chem Pharm Bull (Tokyo); 1991 Sep; 39(9):2465-7. PubMed ID: 1804562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of peptide character of HIV protease inhibitors that exhibit nanomolar potency against multidrug resistant HIV-1 strains.
    Tamamura H; Koh Y; Ueda S; Sasaki Y; Yamasaki T; Aoki M; Maeda K; Watai Y; Arikuni H; Otaka A; Mitsuya H; Fujii N
    J Med Chem; 2003 Apr; 46(9):1764-8. PubMed ID: 12699395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV protease inhibitors: synthesis and activity of N-aryl-N'-hydroxyalkyl hydrazide pseudopeptides.
    Marastoni M; Baldisserotto A; Trapella C; McDonald J; Bortolotti F; Tomatis R
    Eur J Med Chem; 2005 May; 40(5):445-51. PubMed ID: 15893018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 protease inhibitors: ketomethylene isosteres with unusually high affinity compared with hydroxyethylene isostere analogs.
    Marinier A; Toth MV; Houseman K; Mueller R; Marshall GR
    Bioorg Med Chem; 1994 Sep; 2(9):919-25. PubMed ID: 7712127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potency comparison of peptidomimetic inhibitors against HIV-1 and HIV-2 proteinases: design of equipotent lead compounds.
    Weber J; Majer P; Litera J; Urban J; Soucek M; Vondrásek J; Konvalinka J; Novek P; Sedlácek J; Strop P; Kräusslich HG; Pichová I
    Arch Biochem Biophys; 1997 May; 341(1):62-9. PubMed ID: 9143353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Pseudo-Symmetric
    D'Orsi R; Funicello M; Laurita T; Lupattelli P; Berti F; Chiummiento L
    Biomolecules; 2021 Oct; 11(11):. PubMed ID: 34827582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and structure-activity study of shorter hexa peptide analogues as HIV-1 protease inhibitors.
    Narendra Babu SN; Rangappa KS
    Bioorg Med Chem; 2008 Jan; 16(2):874-80. PubMed ID: 17981043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
    Ghosh AK; Sridhar PR; Leshchenko S; Hussain AK; Li J; Kovalevsky AY; Walters DE; Wedekind JE; Grum-Tokars V; Das D; Koh Y; Maeda K; Gatanaga H; Weber IT; Mitsuya H
    J Med Chem; 2006 Aug; 49(17):5252-61. PubMed ID: 16913714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An expedient synthesis of N(alpha)-protected-L-tetrahydrofuranylglycine and its application in the synthesis of novel substrate based inhibitors of HIV-1 protease.
    Rajesh S; Ami E; Kotake T; Kimura T; Hayashi Y; Kiso Y
    Bioorg Med Chem Lett; 2002 Dec; 12(24):3615-7. PubMed ID: 12443788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 protease inhibitors containing statine: inhibitory potency and antiviral activity.
    Fehrentz JA; Chomier B; Bignon E; Venaud S; Chermann JC; Nisato D
    Biochem Biophys Res Commun; 1992 Oct; 188(2):865-72. PubMed ID: 1445327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.